Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL759467 | 0.95 | CA12 (0.61) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL4138078 | 0.94 | CA12 (0.62) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL757089 | 0.90 | TDP1 (0.47) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28006307 | 0.90 | CA1 (0.46) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18352554 | 0.87 | CA12 (0.57) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL16450357 | 0.86 | CA12 (0.54) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL9966901 | 0.85 | TSHR (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL13405231 | 0.85 | TSHR (0.56) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL23746700 | 0.83 | TSHR (0.57) | TSHRALDH1A1CYP3A4HPGDTP53 | |
| SCHEMBL18355340 | 0.83 | CA12 (0.54) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| US-10316316-B2 | Compositions for targeted delivery of siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2019-06-11 | — | — | US | disclosed |
| EP-3023495-B1 | COMPOSITIONS FOR TARGETED DELIVERY OF SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022456-B2 | Reversibly masked polymers | Arrowhead Pharmaceuticals, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2017-07-20 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080287630-A1 | Endosomolytic Poly(Acrylate) Polymers | Arrowhead Pharmaceuticals, Inc. | 2008-11-20 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281044-A1 | Endosomolytic Modified Poly(Alcohol) and Poly(Amine) Polymers | ROCHE MADISON INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080281041-A1 | Reverse deactivation of membrane active polymers; cell delivery; labile bonding of polyamines, polyvinyl alcohol, polyallylamine or polyoxyethylene glycol | Arrowhead Madison Inc. | 2008-11-13 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269450-A1 | Endosomolytic Poly-Beta-Aminoester Polymers | ROCHE MADISON INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10316316-B2 | Compositions for targeted delivery of siRNA | PHAX, RNASE1, SNRPE | CA12 4425/4885CA1 4666/4885CA2 4583/4885 |
| US-10022456-B2 | Reversibly masked polymers | CD47, MSN, EPCAM | CA12 2322/4885CA1 3630/4885CA2 4064/4885 |
| US-20170204408-A9 | Compositions for Targeted Delivery of siRNA | PHAX, RNASE1, SNRPE | CA12 4425/4885CA1 4666/4885CA2 4583/4885 |
| US-20080281074-A1 | Compounds and Methods for Reversible Modification of Biologically Active Molecules | HDAC6, CD47, AADAC | CA12 1322/4885CA1 3569/4885CA2 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.